MAIA Biotechnology (MAIA) Projected to Post Earnings on Friday

MAIA Biotechnology (NYSEAMERICAN:MAIA) is expected to be issuing its Q3 2026 resultson Friday, November 6th. Analysts expect MAIA Biotechnology to announce earnings of ($0.13) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts expect MAIA Biotechnology to post ($0.54) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

MAIA Biotechnology Price Performance

MAIA opened at $1.08 on Wednesday. The firm has a market capitalization of $66.68 million, a PE ratio of -1.74 and a beta of 0.28. The business’s 50-day moving average is $1.23 and its two-hundred day moving average is $1.46. MAIA Biotechnology has a 1 year low of $0.87 and a 1 year high of $3.19.

Insider Transactions at MAIA Biotechnology

In other news, Director Ramiro Guerrero acquired 37,595 shares of MAIA Biotechnology stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $49,625.40. Following the purchase, the director directly owned 773,296 shares in the company, valued at $1,020,750.72. The trade was a 5.11% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Vlad Vitoc acquired 73,000 shares of MAIA Biotechnology stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average price of $1.37 per share, with a total value of $100,010.00. Following the purchase, the chief executive officer owned 1,049,121 shares in the company, valued at $1,437,295.77. This represents a 7.48% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 258,078 shares of company stock worth $352,426 over the last 90 days. Company insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.